Smithers Viscient announces the appointment of Ian Siragher to the position of Managing Director
24.1.2019 13:30:00 EET | Business Wire | Press release
Smithers Viscient, a global contract research organization (CRO), today announced the appointment of Ian Siragher to the position of Managing Director.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190124005031/en/
Ian Siragher, Managing Director, Smithers Viscient Europe (Photo: Business Wire)
Siragher will assume operational responsibility for the Smithers Viscient European site in Harrogate, UK. His experience includes high technology start-ups, running SME business, sales, marketing and regulated industry programs within the analytical, pharmaceutical and drug delivery industries. He brings a wealth of entrepreneurial experience with proven strengths in scientific knowledge, operational and strategic planning, coupled with a strong client focus.
“We are delighted to welcome Ian to our business,” said Susan Shepherd, President, Smithers Viscient. “Ian is an excellent appointment for us; he is a proven operational leader having spent much of his career running a range of businesses.” Shepherd continues, “He brings an exceptionally strong global positioning and planning background, which is vital as we continue to grow our portfolio. His proven experience, vision and his ability to think strategically makes him an excellent choice in support of our clients around the globe.”
Siragher joins Smithers after 12 years as Managing Director and founder with Concept Life Sciences, formerly Agenda 1 Analytical Services Ltd. He holds an MBA, a Bsc (Hons) in Psychology and is an Associate of Chartered Institute of Bankers (ACIB). He has relocated to Harrogate to take up the position.
# # #
About Smithers Viscient
Smithers Viscient is a global contract research organization (CRO). The company delivers a comprehensive range of ecotoxicology, environmental fate, metabolism and chemistry services, for the pharmaceutical, crop protection, chemical, and consumer household product industries. Pollinator testing capabilities include laboratory-based studies, semi-field, and field exposures. With laboratories located in North America and Europe, Smithers Viscient, has performed standard guideline and higher-tiered environmental studies for 45 years. For more information about Smithers Viscient’s environmental regulatory testing solutions, visit http://smithersviscient.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190124005031/en/
Contact information
Smithers Viscient
Fiona Brook-Rogers
Marketing Manager
Europe
+44 (0) 1423 532 710
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma’s Nemluvio ® (nemolizumab) Demonstrates Long-Term Disease Control in Prurigo Nodularis up to Three Years27.2.2026 08:00:00 EET | Press release
Galderma (SIX: GALD) today announced new data from the OLYMPIA open-label extension study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis.1 Results showed that Nemluvio maintained long-term disease control and a well-tolerated safety profile, with clinically meaningful improvements in itch intensity, skin lesions and quality of life up to three years.1 Results will be presented at 2026 Winter Clinical Miami and build on previous data from OLYMPIA – the largest completed pivotal clinical program in prurigo nodularis and the only one with a LTE study.1,6,7 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226796734/en/ “Prurigo nodularis is not only intensely itchy, painful and uncomfortable, it can also take a profound toll on sleep, emotional wellbeing, and daily functioning. That’s why achieving sustained, long-term disease control is critical for patients. These data show
Venture Global Announces New Long-Term LNG Partnership with Hanwha of Korea27.2.2026 02:00:00 EET | Press release
Today, Venture Global, Inc. (NYSE: VG) and Hanwha Aerospace Co., Ltd. announced the execution of a new Sales and Purchase Agreement (SPA) for the purchase of 1.5 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for twenty years starting in 2030. This agreement brings Venture Global’s long-term contracted portfolio to over 46 MTPA. “Venture Global is thrilled to announce our first long-term supply deal in Korea through a new partnership with Hanwha Aerospace which marks another important step in expanding reliable, long-term LNG supply to our partners in Asia,” said Mike Sabel, CEO of Venture Global. “We are proud to support growing global energy needs with low-cost, secure American LNG while strengthening the strategic energy partnership between the United States and South Korea to support long-term industrial and economic growth.” About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (LNG)
Hydnum Steel Secures 500 MW of Electrical Power, a Key Step Forward in the Construction of Its Clean Steel Plant in Spain27.2.2026 01:00:00 EET | Press release
Hydnum Steel has taken a decisive step towards constructing Spain’s first clean steel plant after being granted access to the electricity grid at the Brazatortas node in the province of Ciudad Real. The company has been granted an electricity capacity of 500 MW, as published in the Official State Gazette, which should be enough to guarantee supply to its electric arc furnace. This concession marks a significant milestone for a pioneering project in the Iberian Peninsula. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225309290/en/ Image recreating the steel plant that Hydnum Steel will build in Puertollano, Spain Hydnum Steel is consolidating its position as a reliable supplier of clean European steel. The fully digitally integrated plant will produce hot-rolled steel coils efficiently and sustainably, with benefits for the environment and the economy. Hydnum Steel will deliver a solution for steel-consuming industries th
1089 Inc. Partners with Price Forbes and Oka-Lloyd's Syndicate 1922 to Launch Market-Defining First: Carbon Asset Insurance Framework for Transportation and Energy Sectors27.2.2026 00:01:00 EET | Press release
1089 Inc., in collaboration with Price Forbes and Oka, The Carbon Insurance Company, announce launch of an insured carbon asset designed to bring institutional safeguards, disciplined financial architecture, and verifiable data integrity to carbon markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226012782/en/ 1089 Inc. is Advancing Carbon™, focused on evolving global carbon markets and decarbonizing the highest-emitting sectors on the planet: Transportation and Energy. The framework provides defined risk coverage for 1089’s CX89 Advanced Fuels Carbon Assets, underwritten by Lloyd’s Syndicate 1922 and placed with the support of Price Forbes and Oka. The program introduces institutional-grade protection designed to prevent performance losses resulting from credit degradation between wrapping and minting. Luke Hanley, Founder and CEO of 1089 Inc., shared the framework’s core thesis: “The future of carbon markets is no
Sun Nuclear QADS 2026 Event Combines Clinical Insight and New Innovations for Advancing Radiation Therapy QA27.2.2026 00:00:00 EET | Press release
Sun Nuclear, a Mirion Medical company, today opened the QA & Dosimetry Symposium (QADS), taking place over the next two days in Rome, Italy. The 15th installment brings together more than 230 clinical physicists and radiation medicine professionals from nearly 40 countries. Participants from diverse clinical environments will earn continuing education credits while sharing practical insights, emerging approaches, and real-world experiences shaping the future of quality and patient safety in cancer care. Building on its legacy as a peer-driven forum with practical applications, QADS 2026 features sessions delivered by 24 speakers spanning: Future Directions in Machine and Patient QA and In-vivo Dosimetry Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT) QA Safety and Guideline-driven Tool Selection Emerging Technologies, including Theranostics, AI and Automation Reinforcing its role as a launch point for clinically grounded innovation, QADS 2026 will serve a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom